The European Commission (EC) has granted approval for AstraZeneca’s Ultomiris (ravulizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients.

Approved as the first and only long-acting C5 complement inhibitor, Ultomiris is indicated to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD in the European Union (EU).

It inhibits the C5 protein in the terminal complement cascade, part of the body’s immune system.

The EC’s approval follows a positive opinion from the committee for medicinal products for human use.

AstraZeneca’s subsidiary Alexion CEO Marc Dunoyer stated: “Just four years since delivering the first approved NMOSD treatment to the EU, we are pleased to once again advance the treatment landscape with Ultomiris, which may eliminate relapses for people impacted by NMOSD.

“This approval is the culmination of extensive work and collaboration with the NMOSD community, including patients, caregivers and healthcare providers who participated in the CHAMPION-NMOSD trial, and we’re proud to continue improving access to our innovative medicines worldwide.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The regulatory approval was based on the data obtained from the multicentre, open-label CHAMPION-NMOSD Phase III trial, which assessed the efficacy and safety of Ultomiris in NMOSD adult patients.

Ultomiris met the primary endpoint of time to first on-trial relapse, confirmed by an independent adjudication committee.

The therapy’s safety and tolerability were found to be consistent with that observed in previous clinical trials and real-world use.

AstraZeneca stated that regulatory submissions for Ultomiris are currently under review with health authorities, including those of Japan and the US.